Trial Profile
A stratified multi-arm Phase 2 study evaluating the efficacy and safety of LDE225 in patients with advanced/metastatic sarcomas
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Apr 2022
Price :
$35
*
At a glance
- Drugs Sonidegib (Primary)
- Indications Chondrosarcoma; Ewing's sarcoma; Osteosarcoma; Rhabdomyosarcoma; Soft tissue sarcoma
- Focus Therapeutic Use
- 08 Jun 2016 Status changed from not yet recruiting to active, no longer recruiting.
- 05 Jun 2012 New trial record